Anavex Life Sciences (AVXL) Receivables - Other (2010 - 2025)
Anavex Life Sciences (AVXL) posted Receivables - Other of $700000.0 for Q4 2025, little changed sequentially from $700000.0 in Q3 2025, and down 70.83% YoY from $2.4 million in Q4 2024.
Anavex Life Sciences (AVXL) Receivables - Other (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Receivables - Other for 7 years, with the latest figure at $700000.0 in Q4 2025.
- Quarterly Receivables - Other fell 70.83% year-over-year to $700000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $700000.0 (down 70.83% YoY) and the FY2025 annual result came in at $700000.0, down 69.57% from the prior year.
- Receivables - Other steadied at $700000.0 in Q4 2025 per AVXL's latest filing, from $700000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $2.9 million in Q3 2022 and troughed at $500000.0 in Q1 2025.
- A 4-year average of $1.6 million and a median of $1.5 million in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other dropped 8.0% in 2024, then sank 70.83% in 2025.
- Over 4 years, Receivables - Other stood at $2.9 million in 2022, then dropped by 13.79% to $2.5 million in 2023, then fell by 4.0% to $2.4 million in 2024, then slumped by 70.83% to $700000.0 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $700000.0, $700000.0, and $600000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 2.40 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2012 | -953.00 |
| Jun 30, 2012 | -953.00 |
| Mar 31, 2012 | -2,095.00 |
| Mar 31, 2012 | -2,095.00 |